Landfar(SZ:000504) Di Yi Cai Jing·2025-08-11 13:01Core Viewpoint - The company is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements after the transaction is completed [1] Group 1: Transaction Details - The transaction is currently in the planning stage, and there are uncertainties regarding related matters [1] - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services [1] - This transaction is expected to constitute a significant asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" [1] Group 2: Impact on Company Structure - The acquisition will not involve the issuance of new shares and will not lead to a change in the company's control [1]